Life Sciences Companies Are Looking for Growth. The Real Question Is Where to Find It.

According to IQVIA’s Global Trends in R&D 2026, 79 novel active substances launched globally in 2025, including 30 first-in-class treatments. The five-year total reached 388 novel active substances.

IQVIA also reported longer clinical trial timelines, with inter-trial intervals increasing by approximately three months. These changes make pipeline tracking, development benchmarking, and competitor monitoring increasingly important.

Deloitte’s 2026 Life Sciences Outlook highlights other pressures:

• 44% of surveyed executives identified pricing and market access as major considerations.

• 37% highlighted competition from generics and biosimilars.

• 26% identified patent cliffs as a concern.

• 39% pointed to geopolitical risks.

• 45% of biopharma executives and 51% of medtech executives identified M&A as a near-term priority.

Get Complete Dataset, Company Quadrant and Customized Sample: https://www.towardshealthcare.com/download-sample/5711 

These figures show why companies need to evaluate opportunities alongside commercial risks, competition, and partnership potential.

Where Companies Need Better Intelligence

How Towards Healthcare Supports These Decisions

Towards Healthcare combines healthcare research with business consulting to help life sciences leaders assess opportunities and make informed decisions.

Our work can include:

• Complete master datasets covering companies, products, pipelines, investments, and partnerships.

• Pipeline intelligence to track clinical programs, development stages, competing assets, and key milestones.

• Competitive quadrant analysis to compare companies, technologies, and strategic positioning.

• Buyer and partner identification to identify relevant pharmaceutical companies, biotech firms, CDMOs, investors, and licensing prospects.

• Customized dashboards that bring relevant company, pipeline, deal, and competitor data into one view.

• GTM strategy and opportunity assessment to evaluate target segments, regional priorities, and potential routes to growth.

Unlike a report-only approach, Towards Healthcare connects research findings with practical business questions: Where is the opportunity? Who are the competitors? Which partners should we approach? What should we prioritize next?

Turn Life Sciences Data Into a Business Decision

Whether you are evaluating a new therapeutic area, tracking competitors, planning a product launch, or identifying licensing partners, the right intelligence can help you assess opportunities before committing resources.

Contact Towards Healthcare to discuss a customized research sample aligned with your business priorities.

Website: https://www.towardshealthcare.com

Email: [email protected]